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SUMMARY. The importance of treating hepatitis C virus
(HCV)-associated morbidities in a growing population of
patients coinfected with human immunodeﬁciency virus
(HIV) has increased since the introduction of highly active
antiretroviral therapy. As a result, investigative attention is
turning to HCV-related liver disease and treatment-associ-
ated issues in coinfection. HIV/HCV-coinfected patients have
higher HCV RNA loads and show more rapid progression of
ﬁbrosis than do monoinfected patients. Combination therapy
with pegylated interferon plus ribavirin (RBV) is the stan-
dard of care for HCV in coinfected patients. Therapy slows
ﬁbrosis progression, but toxicity prevents identiﬁcation of the
most effective RBV dose. Coinfected patients have about a
threefold greater risk of antiretroviral therapy-associated
hepatotoxicity than patients with HIV only. Other challenges
include anaemia, mitochondrial toxicity, drug–drug inter-
actions and leucopenia. Thus, chronic hepatitis C should be
treated in HIV/HCV-coinfected patients, but steps must be
taken to prevent and treat potential toxicities. The ﬁrst
European Consensus Conference on the Treatment of Chro-
nic Hepatitis B and C in HIV Co-infected Patients was held
March 2005 in Paris to address these issues. This article
reviews the peer-reviewed literature and expert opinion
published from 1990 to 2005, and compares results with
presentations and recommendations from the Consensus
Conference to best present current issues in coinfection.
Keywords: coinfection, hepatitis C, human immunodeﬁciency
virus, treatment.
INTRODUCTION
Approximately 30% of patients infected with the human
immunodeﬁciency virus (HIV) in the USA and Europe are
also infected with the hepatitis C virus (HCV) [1–3]. The high
prevalence of HIV/HCV coinfection is not unexpected
because both viruses are transmitted by the same routes,
although not with the same efﬁciency. As a result, the
prevalence of HIV/HCV coinfection varies across subpopu-
lations of HIV-infected patients; for example, persons
acquiring HIV through exposure to contaminated blood
(such as injection drug users or haemophiliacs) are more
likely to have HCV coinfection than those acquiring HIV
through sex [4].
Since the introduction of highly effective antiretroviral
therapy (HAART) in the mid-1990s, liver disease has
emerged as an important cause of morbidity and mortality in
HIV-infected patients. As HIV-related mortality has declined,
hepatitis C-related liver disease has become a leading cause
of hospitalization and death in this population [5]. Chronic
hepatitis C infection is now the most common indication for
liver transplantation in the USA [6], and some estimates
suggest that the number of deaths from HCV in the USA and
Europe will triple over the next 10 years to surpass the
number of deaths from AIDS.
Hepatologists and infectious disease specialists are
increasingly turning their attention to HIV/HCV coinfection
and its treatment. An international community of hepatol-
ogists, infectious disease specialists and others convened the
ﬁrst European Consensus Conference on the Treatment of
Hepatitis B and C in HIV Co-infected Patients March 1 to 2,
2005, in Paris, France. This paper reviews the therapeutic
issues affecting this coinfected population of patients and
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NATURAL HISTORY OF HIV/HCV COINFECTION
Both HIV, a retrovirus, and HCV, a ﬂavivirus, are single-
stranded RNA viruses that produce chronic infection. Both
viruses are also able to evade host immune responses, in part
because of a high mutation rate resulting from rapid repli-
cation and a lack of proofreading capabilities. The estimated
daily virion production rate is 10
10 in patients infected with
HIV and 10
12 in patients infected with HCV [7,8]. Both HIV
and HCV exist in humans as a collection of closely related
clones (e.g. quasispecies) that may evolve differently in such
compartments as the liver, plasma and peripheral blood
mononuclear cells (PBMNCs) [9,10]. In patients infected
with HIV, antiviral drug therapy exerts selection pressure
that may lead to the emergence of drug-resistant strains in
the absence of adequate viral suppression, although speciﬁc
anti-HCV drugs (e.g. HCV protease and polymerase inhibi-
tors) are not yet commercially available, drug resistance to
HCV protease inhibitors has been observed in early in vivo
studies [11].
The presence of both HIV and HCV infection may com-
plicate the natural history of both viruses and their treat-
ment (Table 1) [12–18]. For example, coinfected patients
have higher HCV viral loads than patients infected with HCV
alone. In addition, HIV infection and related immunosup-
pression in patients with hepatitis C may be associated with
more rapid progression of liver disease to cirrhosis, end-stage
liver disease and death. In some studies, HIV/HCV coinfec-
tion was associated with a more rapid progression to AIDS
and death [12]. HCV infection and related liver disease may
be associated with an increased risk of antiretroviral therapy
(ART)-induced hepatotoxicity, complicating the efforts to
treat HIV disease [19].
Liver damage in HIV/HCV-coinfected patients has a
number of potential causes including pre-existing liver dis-
ease (e.g. hepatitis B, D), alcohol abuse, opportunistic
infections (Mycobacterium avium complex), nonalcoholic
steatohepatitis, hepatotoxicity related to drugs used to treat
HIV and its complications, and AIDS cholangiopathy in
patients with CD4
+ cell counts <100/lL. Since the intro-
duction of HAART, liver-related morbidity and mortality has
increased markedly in HIV-infected patients, particularly
those coinfected with hepatitis C. The rate of liver-related
complications increased from 5.4 to 26.7 admissions per
100 patient-years in HIV/HCV-coinfected patients treated at
a large urban hospital between 1995 and 2000 (P < 0.001)
[20]. In addition, liver disease was the second leading cause
of death (0.23 cases per 100 person-years) behind HIV/AIDS
(0.59 cases per 100 person-years) and ahead of cardiac
disease (0.14 cases per 100person-years) among 23 441
patients enrolled in the Data Collection on Adverse Events of
Anti-HIV Drugs (D:A:D) study [21].
INFLUENCE OF HCV ON HIV DISEASE
The mechanisms by which HCV potentially affects HIV dis-
ease are not known; however, some experts speculate that
HIV disease may be accelerated by HCV-related immune
activation and subsequent impairments in immune recovery
after effective ART. In a study of 3111 Swiss patients
receiving HAART, Greub et al. [22] observed that HCV in
HIV-infected patients was independently associated with an
increased risk of progression to AIDS and AIDS-related
death. The authors suggest that this ﬁnding is related to
impaired CD4
+ cell recovery in HCV-seropositive patients
receiving potent ART. However, since HIV-monoinfected
persons differ substantially from those with HIV/HCV coin-
fection with respect to many important social and medical
characteristics (e.g. drug and alcohol use, psychiatric dis-
ease), the researchers may have been unable to adjust for all
potential confounding factors that might be associated with
poor outcomes in coinfected persons [22]. Others have
suggested that HCV genotype might affect outcome in
coinfected patients [23].
Several other studies suggest that HCV coinfection does
not affect HIV disease progression or response to ART. Sul-
kowski et al. [24] failed to identify an independent relation-
ship between HCV infection and HIV disease in several
cohorts after adjusting for potential confounders such as
ART and its effectiveness. In a 6-year cohort study of 1995
coinfected patients, these investigators found no increase in
the rate of progression to an AIDS-deﬁning condition [1.03;
95% conﬁdence interval (CI): 0.86–1.23] or death (1.05;
95% CI: 0.85–1.30) [24]. In addition, after adjusting for HIV
treatment, HCV infection was not independently associated
with death in the subsets of patients with CD4
+ counts of 50
to 200 cells/lL. Furthermore, mortality did not differ
between HIV-infected and HIV/HCV-coinfected patients
receiving effective HAART, and no differences were found in
increases in CD4
+ cell count or CD4
+ percentage during
administration of HAART [25]. These data suggest that
there are no major differences in HIV-related mortality be-
tween patients infected with both HIV and HCV and patients
infected with HIV alone receiving ART.
INFLUENCE OF HIV ON HCV DISEASE
HIV/HCV coinfection has been consistently associated with
progression of HCV disease [17,26]. Because HAART has
decreased HIV-speciﬁc mortality, HCV has become a major
problem in coinfected patients.
Accelerated ﬁbrosis progression
Compared with those without HIV, coinfected patients have
higher HCV RNA levels and more rapid progression of hep-
atic ﬁbrosis [16]. Factors associated with progressive ﬁbrosis
included advanced immunodeﬁciency (CD4
+ cell counts
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Treatment of HIV/HCV-coinfected patients 373<200/lL), higher daily alcohol consumption rate and older
age at HCV infection. Benhamou et al. [17] compared the
natural history of HCV disease in 244 matched patients
divided equally into those with and those without HIV co-
infection. The prevalences of signiﬁcant liver ﬁbrosis
(METAVIR ﬁbrosis scores 2–4) and moderate or severe
inﬂammatory activity were higher in HIV-infected patients
(60% and 54%, respectively) than in the non-HIV-infected
patients (47% and 30%, respectively; P < 0.05 and
P < 0.001). The investigators used ﬁbrosis stage (METAVIR
scoring system) and estimated duration of HCV infection to
determine a ﬁbrosis progression rate. The median ﬁbrosis
progression rates in coinfected and control patients were
0.153 ﬁbrosis U/year (95% CI: 0.117–0.181) and 0.106
ﬁbrosis U/year (95% CI: 0.084–0.125), respectively
(P < 0.001 for the difference of 0.047 ﬁbrosis units between
group medians).
Preliminary evidence suggests that effective ART may
slow the ﬁbrosis progression rate in coinfected patients [27].
However, other studies show that ART can be associated
with increased liver enzyme levels and hepatic steatosis in
some patients, particularly those with hepatitis C. Further
research is needed to determine the long-term effect of ART
on the progression of liver disease in coinfected patients.
Progression to cirrhosis and hepatocellular carcinoma
Compared with HCV infection alone, HIV/HCV coinfection is
associated with an increased risk of cirrhosis, end-stage liver
disease and hepatocellular carcinoma. Graham et al. [15]
conducted a meta-analysis of eight studies in coinfected pa-
tients to evaluate the risk of progression to decompensated
liver disease and histologically established cirrhosis. The
pooled, adjusted relative risk (RR) of developing histologi-
cally conﬁrmed cirrhosis was 2.07 (95% CI: 1.40–3.07), and
the RR of developing decompensated liver disease was 6.14
(95% CI: 2.86–13.20). Other investigators reported that
coinfected patients who went on to develop hepatocellular
carcinoma were younger (42.2 vs 68.9 years; P < 0.001)
and had a shorter duration of disease (17.8 vs 28.1 years;
P < 0.05) at the time of diagnosis than HIV-negative
patients [28].
Hepatitis C viremia
Human immunodeﬁciency virus-mediated immune sup-
pression appears to facilitate HCV replication, impair im-
mune-mediated HCV clearance or both. Studies demonstrate
that coinfected patients have signiﬁcantly higher serum HCV
titres than do patients infected with HCV alone [29,30]. This
association is independent of HCV genotype [31] and, in
some studies, is linked to lower CD4
+ cell counts as well,
suggesting a relationship between viremia and cellular and
innate immunity. Whereas HCV is predominantly hepato-
trophic, hepatitis C may also replicate in PBMCs [32]. In an
in vitro study of PBMCs from healthy donors, HIV infection
increased the susceptibility of macrophages to HCV infection
[33]. In fact, HIV coinfection appeared to be required to
establish HCV replication in this cell line. Interestingly, im-
mune reconstitution following effective ART has been asso-
ciated with transient increases in the levels of hepatitis C
viremia followed by a return to pre-ART levels. However,
suppression of hepatitis C viremia following effective ART
has not been consistently observed, suggesting additional
factors may be responsible for the association of HIV and
HCV load [34].
Risk of ART-associated hepatotoxicity
Whereas ART should not be withheld from coinfected pa-
tients requiring HIV treatment, chronic hepatitis C is asso-
ciated with an increased risk of drug-induced hepatotoxicity
(Table 2) [35,36]. In a study of HIV-infected patients
receiving HAART, HCV infection was associated with a 2.46
increased RR (95% CI: 1.43–4.24) for liver enzyme eleva-
tions (5 · upper limit of normal) and an absolute increase of
at least 100 U/L [37]. In a study of other HAART-associated
risk factors, the following were also associated with in-
creased RRs for liver toxicity: alcohol abuse (RR 5.87; 95%
CI: 1.49–23.15; P ¼ 0.01), HCV coinfection (RR 3.99; 95%
CI: 1.32–12.10; P ¼ 0.01) and older age (RR 1.11; 95% CI:
1.04–1.18; P ¼ 0.001) [38]. Across several studies, the risk
of liver injury appears to be particularly great with the use of
nevirapine and full-dose ritonavir; however, the adminis-
tration of low-dose ritonavir (£200 mg/day) has not been
associated with a greater risk of hepatotoxicity. The mech-
anisms underlying the association of HCV and hepatotoxic-
ity have not been fully described, but in some patients liver
enzyme elevations may be a manifestation of immune
reconstitution that follows ART. After immune recovery,
CD4
+ cell counts rise and the ability of immunocytes to
identify and lyse HCV-infected hepatocytes may be increased
[39]. However, there is little direct evidence of this phe-
nomenon in vivo and alternative mechanisms of liver injury
probably contribute.
EFFECTS OF HAART IN COINFECTED PATIENTS
Overall, HAART slows the progression of hepatic ﬁbrosis in
coinfected patients. Qurishi et al. [40] reported a Kaplan–
Meier analysis of liver-related mortality and conﬁrmed that
ART signiﬁcantly improves survival in coinfected patients
(P ¼ 0.02). Regression analysis identiﬁed the following fac-
tors as being signiﬁcantly associated with liver-related sur-
vival (Fig. 1): HAART [odds ratio (OR) 0.12 (95% CI: 0.02–
0.56)], antiretroviral treatment [OR 0.28 (95% CI: 0.10–
0.78)], CD4
+ T-cell count [OR 0.75 (95% CI: 0.64–0.87) per
0.05 · 10
9 cells/L], serum cholinesterase [OR 0.96 (95% CI:
0.94–0.99) per 100 U/L], and older age [OR 1.07 (95% CI:
1.03–1.11) per year] [41].
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374 M. S. Sulkowski & Y. BenhamouA study by Marine-Barjoan et al. [42] supported these
results and showed that coinfected patients treated with
HAART had slower progression of hepatic ﬁbrosis and that
ﬁbrosis was more likely to develop when HAART therapy
was delayed. Thus, although ART may be associated with
hepatotoxicity in some HCV-coinfected patients, emerging
evidence suggests that control of HIV disease confers some
histologic and clinical beneﬁt in HCV-infected patients.
TREATING HCV INFECTION IN COINFECTED
PATIENTS
The goal of therapy for chronic hepatitis C is viral eradica-
tion or sustained virologic response (SVR), an outcome
associated with improved histologic results and decreased
risk of progression to cirrhosis, end-stage liver disease and
hepatocellular carcinoma.
Screening
Because the prevalence of coinfection is high, all HIV-infec-
ted patients should always be screened for HCV using a
third-generation enzyme-linked immunoblot assay [43].
Because HIV and HCV share risk factors, HCV-infected pa-
tients should also be screened for HIV. Persons found to be
positive for HCV antibodies should also be tested for serum
HCV RNA, as the detection of viremia indicates active dis-
ease. Patients with advanced HIV disease (CD4
+ cell count
<100/lL) and those with acute HCV infection may not have
detectable HCV antibodies. Accordingly, HCV RNA testing
should also be done if HCV is clinically suspected after a
negative HCV antibody result. Coinfected patients should
also be screened for protective immunity against hepatitis B
and A infection and, in the absence of past infection, vac-
cinated.
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Fig. 1 Kaplan–Meier analysis of liver-related mortality. To
calculate liver-related mortality, deaths because of nonhe-
patic causes were censored. Vertical marks indicate cen-
sored patients. ART, antiretroviral therapy; HAART, highly
active antiretroviral therapy. (Reprinted with permission
from Qurishi et al. [40]).
Table 2 Incidence and relative risk of severe hepatotoxicity associated with highly active antiretroviral therapy*
Antiretroviral drug regimen n Cases
Person-
time (100
person-
months)
Incidence (cases/
persons exposed)
(95% CI)
Incidence (cases/100
person-months)
(95% CI)
Relative risk
(95% CI)
Dual nucleoside analogue 87 5 246 5.7 (1.2–12.9) 2.0 (0.7–4.7) 1.0
Protease inhibitor (all) 112 26 795 12.3 (8.2–17.5) 3.3 (2.1–4.8) 2.2 (0.9–5.4)
Ritonavir (single protease inhibitor) 22 6 96 27.3 (10.7–50.2) 6.3 (2.3–21.6) 4.8 (1.6–14.1)
Ritonavir plus saquinavir 28 9 79 32.1 (15.9–52.4) 11.4 (5.2–21.6) 5.6 (2.1–15.3)
Saquinavir 17 1 98 5.9 (0.15–28.7) 1.0 (0.7–4.8) 1.0 (0.1–8.2)
Indinavir 117 8 520 6.8 (3.0–13.1) 1.5 (0.7–3.0) 1.2 (0.4–3.5)
Nelﬁnavir 51 3 153 5.9 (1.2–16.2) 2.0 (0.4–5.7) 1.0 (0.3–4.1)
Total 298 31 1041 10.4 (7.2–14.4) 3.1 (2.1–4.3) NA
Reprinted with permission from Sulkowski et al. [35].
CI, conﬁdence interval; NA, not applicable; PEG-IFN, pegylated interferon; RBV, ribavirin.
*Because use of individual drugs was studied, some overlap occurred during the study period; thus, the individual numbers of
patients and cases and the person-time for speciﬁc protease inhibitor categories do not equal the Total.
Saquinavir hard gelatin capsule formulation without concurrent ritonavir prescription. The case occurring in a patient
receiving saquinavir alone (i.e. not in combination with ritonavir) is also counted in the indinavir category because the patient
was taking both drugs at the time of the toxicity.
  2006 The Authors
Journal compilation   2006 Blackwell Publishing Ltd
Treatment of HIV/HCV-coinfected patients 375The decision to perform a liver biopsy should be made on a
patient-by-patient basis. Liver histology indicates the grade
and stage of HCV-related liver disease and may also provide
information about comorbidities such as alcoholic liver dis-
ease, nonalcoholic steatohepatitis and mitochondrial toxic-
ity. However, histologic staging may be less important in
patients in whom HCV treatment is likely to be effective as
treatment may be beneﬁcial regardless of histologic stage
(e.g. genotypes 2, 3 and/or genotype 1 with low viral load).
Persons with cirrhosis should be screened on a semi-annual
basis for hepatoma with serum alpha-fetoprotein and liver
imaging studies [e.g. ultrasound, computed tomography
(CT), magnetic resonance imaging]. Upper endoscopy may
also be indicated in cirrhotic patients to evaluate and man-
age potential esophageal varices.
Because of the limitations, expense and risks of biopsy,
noninvasive markers of liver disease are highly desirable.
Unfortunately, alanine aminotransferase levels do not cor-
relate well with the histologic severity of liver disease, and
normal levels do not exclude the presence of signiﬁcant
hepatic ﬁbrosis. As a result, investigators have studied a
number of noninvasive approaches to evaluation of the stage
of liver disease in patients with chronic hepatitis C. Transient
elastography (FibroScan
 ; EchoSens, Paris, France) meas-
ures liver stiffness as a rapid and reproducible surrogate of
hepatic ﬁbrosis [44]. A panel of biochemical markers has
been used to estimate the degree of hepatic ﬁbrosis and
activity (HCV FIBROSURE
TM Laboratory Corporation of
America, Research Triangle Park, NC, USA). At a cut-off
value of 0.31 and 0.36, the two tests had negative predictive
values 91% for excluding cirrhosis and 85% for excluding
signiﬁcant necrosis [45]. A retrospective analysis of 832
patients from the AIDS Pegasys Ribavirin International Co-
infection Trial (APRICOT) identiﬁed platelet count, age, and
alanine and aspartate aminotransferase levels as signiﬁ-
cantly different, varying with stage of ﬁbrosis: F0–1, F2–3
and F4–6 [46]. Investigators used an equation that included
these variables to create an index (FIB-4). With a cut-off
outside of 1.45–3.25, the FIB-4 index correctly classiﬁed
87% of patients in the APRICOT subset according to stage of
ﬁbrosis. Use of the FIB-4 would have resulted in a 71% de-
crease in biopsies for staging. Although this evolving evi-
dence suggests that such laboratory tests can replace liver
biopsy in the work-up of coinfected patients, signiﬁcant
ﬁbrosis can still be missed or misdiagnosed [47].
Identifying candidates for therapy
Published treatment guidelines recommend the provision of
HCV treatment to HIV-infected patients for whom the
potential beneﬁts of therapy outweigh the potential risk of
treatment-related toxicity. SVR rates are relatively high
( 60%) in persons with HCV genotype 2 or 3 and with HCV
genotype 1 and relatively low levels of hepatitis C viremia
(HCV RNA < 800 000 IU/mL). Conversely, SVR rates are
signiﬁcantly lower ( 18%) in persons with HCV genotype 1
and relatively high levels of viremia.
In addition to viral parameters, host factors also predict
HCV treatment response. For example, host genetic factors
may play a role particularly with respect to signiﬁcantly
lower SVR rates (50%) observed among African-American
than among white American patients with hepatitis C [48].
Interestingly, in several large studies, HIV disease (e.g. low
CD4 cell count, high HIV RNA level) and its treatment were
not associated with HCV treatment response. Conversely,
hepatitis C disease stage may affect response rates. In most
studies, SVR is more common among those with no or
minimal hepatic ﬁbrosis compared with those with bridging
ﬁbrosis or cirrhosis. However, HCV may be eradicated in
patients with advanced ﬁbrosis, and the impetus to treat
such patients before hepatic decompensation is strong.
Interferon (IFN)-based therapy is contraindicated in patients
with decompensated liver disease (Child–Pugh stage B or C).
The decision to treat hepatitis C must take into account
comorbid conditions that limit life expectancy or increase the
risks associated with HCV therapy; for example, HIV disease
should be stable with or without ART. Because IFN can
exacerbate pre-existing mental illness, persons with under-
lying psychiatric disease, such as depression or bipolar dis-
order, should be evaluated before HCV treatment is initiated.
Similarly, although HCV treatment is not contraindicated in
persons actively using illicit drugs or alcohol, substance
abuse is associated with high rates of treatment nonadher-
ence and may compromise treatment outcomes.
THERAPEUTIC OPTIONS FOR HCV IN HIV-
INFECTED PATIENTS
Candidates for HCV therapy should be patients in whom the
potential beneﬁts of treatment exceed the potential risks. HIV
disease status is a major consideration is this risk:beneﬁt
assessment. For patients with relatively high CD4
+ cell
counts (>350/lL) for whom ART may be deferred, HCV
treatment may be considered. Conversely, patients with low
CD4
+ cell counts (<200/lL) with untreated HIV infection
should not receive HCV therapy until HIV infection is
effectively treated.
Recommended HCV therapy in coinfected patients
Published guidelines for anti-HCV therapy [49–51] indicate
that the standard of care in coinfected patients is pegylated
IFN alfa (PEG-IFN) plus ribavirin (RBV) (Table 3) [52–58].
Efﬁcacy and safety outcomes after treatment of HIV/HCV
coinfection were published recently by investigators from
APRICOT and from the Randomized Controlled Trial of
Pegylated-Interferon alfa-2b plus Ribavirin vs Interferon
alfa-2b plus Ribavirin for the Initial Treatment of Chronic
Hepatitis C in HIV Co-Infected Patients (RIBAVIC) [57,59].
Both trials compared standard IFN alfa-2a or alfa-2b and the
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376 M. S. Sulkowski & Y. Benhamoupegylated formulations of these IFNs for 48 weeks inde-
pendent of HCV genotype [57,59]. All patients also received
RBV 800 mg/day; although lower than routinely given to
noncoinfected patients, this dosage was selected because of
concerns about RBV-associated anaemia and possible drug–
drug interactions between RBV and nucleoside reverse
transcriptase inhibitors.
Pegylated-IFN plus RBV was signiﬁcantly more effective
than standard IFN plus RBV in both APRICOT and RIBAVIC
[57,59]. The APRICOT investigators reported the highest
SVR rate achieved in coinfected patients treated with PEG-
IFN rather than standard IFN plus RBV: an overall SVR rate
of 40% vs 12% (genotype 1, 29% vs 7%; genotypes 2, 3, 62%
vs 20%, respectively). In patients with cirrhosis, a group that
is difﬁcult to treat, the SVR rate was 30%. Although RIBA-
VIC also demonstrated superiority of PEG-IFN plus RBV, the
improvement in outcomes was less than anticipated. The
overall SVR in RIBAVIC was 27% vs 20% (genotype 1 or 4,
17% vs 6%; genotype 2, 3, or 5, 44% vs 43%).
Several factors potentially account for the lower SVR rates
in RIBAVIC: [1] early treatment discontinuations and [2]
proportion of patients with bridging ﬁbrosis or cirrhosis
[57,59]. Early treatment discontinuations were more com-
mon in RIBAVIC than in APRICOT (37% vs 15%) and were
predominantly related topatientsdecisions tostoptherapyor
not to return for further treatment to avoid serious adverse
events (16% vs 13%, respectively). In addition, more patients
inRIBAVIChadbridgingﬁbrosisorcirrhosisthaninAPRICOT
(40% vs 16%), representing a population with lower expected
HCV treatment efﬁcacy andtolerability. The high incidence of
adverse events in the two trials is a reminder that coinfected
patients with advanced liver disease should be monitored
particularly closely for drug-related toxicities. In addition,
coinfected patients receiving combination therapy for HCV
should not be also receiving didanosine, a drug associated
with signiﬁcant mitochondrial toxicity. Didanosine toxicity is
believed to result from increased phosphorylation of the drug
because of inosine monophosphate dehydrogenase (IMPDH)
inhibition by RBV, leading to an increased effect on mitoch-
ondrial DNA polymerase gamma [60].
Findings by Laguno et al. [61] support the results of APRI-
COT, although Laguno et al. had fewer enrollees and their
analysis grouped genotypes 1 and 4. In this randomized, sin-
gle-center, open-label trial, investigators compared the efﬁc-
acy and safety of 48 weeks of standard IFN (3 · 10
6 U TIW)
and PEG-IFN (100–150 lg/week) plus RBV (800–1200 mg/
day) in 95coinfected patients. Patients withHCV genotypes 2
or 3 and baseline HCV RNA levels <800 000 IU/mL received
only 24 weeks of treatment. Intent-to-treat analysis showed
that SVR rates were signiﬁcantly higher among patients
treated with PEG-IFN plus RBV than among patients treated
with standard IFN (44% vs 21%; P ¼ 0.017). The SVR rate
was 38% among patients with genotype 1 or 4 treated with
PEG-IFN but only 7% among patients treated with standard
IFN(P ¼ 0.007).DifferencesinSVRrateswerenotsigniﬁcant
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Treatment of HIV/HCV-coinfected patients 377in patients with HCV genotypes 2 or 3 (53% vs 47%; P ¼
0.730). The CD4
+ cellcount butnot itspercentage droppedin
bothtreatmentgroups,andHIVRNAviralloaddidnotchange
from baseline. The superiority of PEG-IFN plus RBV over
standard IFN was also shown in a similar multicenter,
randomized trial conducted by Chung et al. [62], who dem-
onstratedthattreatmentmaybebeneﬁcialevenintheabsence
ofanSVR:35%of66patientswhodidnotachieveanSVRhad
improved liver histology.
Side effects were common in the APRICOT, RIBAVIC and
Laguno et al. [57,59,61] studies; treatment was discontinued
for adverse events in 12%, 17% and 17% of patients,
respectively, treated with PEG-IFN plus RBV. Hepatic
decompensation, an outcome not anticipated in HCV mo-
notherapy trials, was identiﬁed in substantial numbers of
patients in APRICOT and RIBAVIC but not in Laguno et al.
[63]. All episodes developed in cirrhotic patients. Other risk
factors associated with this event were hyperbilirubinemia;
elevated alkaline phosphatase and decreased haemoglobin
(Hb) or platelet concentrations; and treatment with didan-
osine. There was no correlation with HCV RNA, histologic
activity, CD4
+ cell counts, or combination therapy with
either PEG-IFN or standard IFN.
In the coinfected patient, PEG-IFN is administered at either
180 lg (PEG-IFN alfa-2a) or 1.5 lg/kg (PEG-IFN alfa-2b).
At this time, the dose of RBV for the treatment of HCV in the
HIV-coinfected patient is not well deﬁned. Although most
clinical trials in this population studied ﬁxed doses of RBV
(800 mg/day), data from studies of HIV-seronegative pa-
tients indicate that higher doses of RBV (1000–1200 mg/
day) are more effective than lower doses (800 mg/day) in
persons infected with HCV genotype 1 [64–66]. Logistic
regression analysis of the results of the study by Manns et al.
[64] indicated that RBV dose (in mg/kg) was a signiﬁcant
predictor of SVR. Therefore, although clinical trials in coin-
fected patients generally administer RBV at 800 mg/day,
dosages of 1000 to 1200 mg/day are recommended for pa-
tients with HCV genotype 1 [43]. This recommendation is
supported by ﬁndings from Laguno et al. [61], who reported
that patients were treated with weight-based RBV dosages
(800–1200 mg/day) without safety concerns. More
importantly, in a prospective, randomized, controlled trial in
HIV-seronegative patients, Hadziyannis et al. [67] reported
that both the dose of RBV and total duration of combination
therapy should be individualized according to HCV genotype.
Patients with HCV genotype 1 require treatment with a
standard dose of RBV for 48 weeks. However, those with
HCV genotype 2 or 3 infection appear to be adequately
treated with combination therapy with the low dose of RBV
(800 mg/day) for only 24 weeks.
Unresolved issues in HCV treatment
Unresolved issues include the duration of HCV therapy,
optimal RBV dose for HCV genotype 1 and role of newer
agents. In clinical trials in coinfected patients, the duration
of therapy for all HCV genotypes was 48 weeks. Currently,
the standard of care for patients infected with HCV is
48 weeks for genotype 1 and 24 weeks for genotype 2 or 3.
Preliminary studies suggest that all patients be treated for
48 weeks. Treatment for 24 weeks in HIV-infected patients
with HCV genotype 2 or 3 infection is associated with a high
rate of relapse at the end of therapy [61]. Recent data from
HCV treatment in HIV seronegative patients indicate that
the duration of HCV treatment should be determined by the
viral response kinetics of the individual patient rather than a
standard duration of therapy for all patients. For example,
PEG-IFN plus RBV for 24 weeks was as effective as 48 weeks
among HCV genotype 1-infected patients who achieved an
undetectable HCV RNA level after 4 weeks of treatment
[68,69]. Conversely, the relapse rate was >50% among HCV
genotype 1-infected patients who achieved an undetectable
HCV RNA level for the ﬁrst time after 24 weeks of therapy,
suggesting longer treatment may be needed [70]. Further
research is needed to clarify the appropriate duration of HCV
treatment in coinfected patients as well as the role of indi-
vidual viral kinetics in determining the appropriate treat-
ment course.
Studies in monoinfected patients demonstrated that RBV
signiﬁcantly increases SVR rates [71,72]. Studies in coin-
fected patients generally used low-dose RBV (800 mg/day).
The Spanish Pegasys Plus Ribavirin for HCV Treatment in
HIV/HCV Coinfection (PRESCO) trial looked at efﬁcacy and
safety of PEG-IFN alfa-2a plus RBV for the treatment of
chronic hepatitis C in HIV-coinfected patients [73]. This
trial enrolled 582 coinfected patients to receive PEG-IFN
alfa plus weight-based dosages of RBV (1000/1200 mg/
day). The duration of treatment was extended beyond that
of APRICOT and RIBAVIC (genotypes 1, 4: 12 or 18
months; genotypes 2, 3: 6 or 12 months). The end-of-
treatment response in PRESCO was 50%—12% higher than
that reported in APRICOT — which suggests that higher
doses of RBV may be beneﬁcial [59]. Furthermore, pre-
liminary analysis also suggests that higher doses of RBV
were not associated with an excessive risk of anaemia and/
or mitochondrial toxicity.
A number of newer therapeutic agents in development
include cellular IMPDH or IMPDH inhibitors, viral key
enzyme inhibitors (i.e. protease, helicase and polymerase
inhibitors), internal ribosomal entry site inhibitors, small
and expressed interfering RNAs, ribozymes and several new
IFNs (i.e. IFN alfa-2b fused with albumin, consensus IFN and
IFN-c) [74,75]. Several RBV-like molecules also in develop-
ment have the potential to improve the outcomes compared
with standard RBV.
Assessing response
Early virologic response (EVR) assessed after 12 weeks of
therapy is an important indicator of virologic failure. The
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378 M. S. Sulkowski & Y. Benhamoufailure to achieve an undetectable HCV RNA level or
reductions in HCV RNA ‡2 log10 has a negative predictive
value of 98–100% for treatment failure [76]. Therefore, HCV
treatment should be discontinued if an adequate EVR is not
achieved at 12 weeks. Patients should be made aware of the
importance of strict adherence to dose and schedule during
the ﬁrst 3 months of combination therapy to increase the
probability of achieving an EVR. Similar to HCV RNA levels
during treatment in monoinfected patients, levels in coin-
fected patients at 24 weeks should determine further ther-
apy among those with detectable HCV RNA after 12 weeks
of therapy: treatment should be discontinued in those with
detectable HCV RNA after 24 weeks and continued in those
without. Some experts recommend the continuation of
therapy in patients with marked hepatic ﬁbrosis or cirrhosis
and virologic failure as a means to prevent liver disease
progression. However, the beneﬁts of this approach are
currently unclear and require additional evidence before
being incorporated into practice.
Other treatment-related issues
CD4
+ cell threshold for treatment
Published guidelines do not provide a consensus CD4
+
threshold for treating hepatitis C in HIV/HCV-coinfected
patients. Whereas the American Association for the Study of
Liver Diseases and the Infectious Diseases Society of America
do not specify a threshold, an International Expert Opinion
Panel and the Centers for Disease Control recommend
thresholds of 200 and 500 cells/lL, respectively [49–51]. In
the major randomized clinical trials of treatments for coin-
fected patients [i.e. by RIBAVIC, APRICOT and AIDS Clinical
Trial Group (ACTG) investigators], baseline CD4
+ cell count
had no effect on SVR rates; however, eligible patients in
these studies were required to have baseline counts ‡200/lL
with the exception of APRICOT, in which persons with CD4
+
counts 100–200/lL and HIV RNA levels >5000 copies/mL
were enrolled.
Effect of IFN on CD4
+ cell count
Soriano et al. [77] reported marked decreases in the abso-
lute CD4
+ cell counts in HIV-infected patients with chronic
hepatitis C treated with IFN. A similar observation was
made in the APRICOT, RIBAVIC and ACTG studies, in
which combination PEG-IFN plus RBV signiﬁcantly lowered
the absolute CD4
+ cell counts in coinfected patients [62].
However, in each study, the CD4 cell percentage, repre-
senting the proportion of the total lymphocyte count, was
increased and the absolute CD4
+ cell count returned to
baseline within 24 weeks after treatment was stopped.
Furthermore, in APRICOT, PEG-IFN was associated with an
approximate 0.7 log10 reduction in HIV RNA, conﬁrming a
modest antiretroviral effect of PEG-IFN in some patients. In
addition, HIV-related opportunistic infections were rarely
observed in the published studies. Thus, combination PEG-
IFN and RBV does not appear to be detrimental to HIV
disease.
Treatment of relapsed patients
By deﬁnition, a relapsed patient has undetectable HCV RNA
at the end of treatment and emerging viremia after treat-
ment is stopped. At present, no treatment strategies address
relapse in coinfected patients. However, possible strategies to
produce an SVR in this population include extending the
duration of therapy, administering higher RBV doses, or
deferring treatment until other classes of HCV therapy are
introduced. An effort should be made to determine the pre-
viously administered dose and duration of treatment in pa-
tients considered to have relapsed. If the relapsing patients
received suboptimal doses, retreatment with PEG-IFN plus
RBV at recommended doses and duration of therapy may
produce SVR. Alternatively, if the relapsed patient had dose
reductions because of anaemia, retreatment and concomit-
ant recombinant human erythropoietin (rHuEPO) to main-
tain RBV dose might be considered.
Treatment of nonresponders
Human immunodeﬁciency virus/HCV-coinfected patients
are deemed nonresponders if they adhered to therapy and
did not achieve an EVR at week 12 (<2 log10) or 24 (un-
detectable HCV RNA). Management strategies for these pa-
tients have not been studied but may depend on ﬁbrosis
stage. In patients with minimal ﬁbrosis, treatment might be
deferred until newer classes of anti-HCV drugs become
available. There is evidence from the ACTG 5071 trial that
therapy can improve histologic measures, irrespective of
viral response [62]. Therefore, patients with marked ﬁbrosis
might be retreated with high-dose combination therapy or
treated with maintenance PEG-IFN. However, the absence of
data precludes consensus recommendation regarding the
appropriate management of such patients.
LIVER TRANSPLANTATION
Liver transplantation is the primary treatment option for
eligible coinfected patients with Child–Pugh stage B or C
liver disease [43]. HAART therapy has signiﬁcantly
improved short- and mid-term outcomes in HIV-infected
patients undergoing liver transplantation. In a study by
Ragni et al. [78], cumulative survival among 24 HIV-posit-
ive HAART recipients was similar to that among age- and
race-comparable HIV-negative recipients (P ¼ 0.37, by log-
rank test). At 12, 24 and 36 months after orthotopic liver
transplantation, respective survival rates were 87.1%,
72.8% and 72.8% among HIV-positive patients and 86.6%,
81.6% and 77.9% among HIV-negative patients. However,
HCV infection was associated with compromised patient
survival (P ¼ 0.02). The major issue in this HCV-coinfected
subpopulation is reinfection of the graft — an outcome that
may lead to rapid development of cirrhosis in the graft [52].
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RBV combination therapy for the ﬁrst 3 months after
transplantation. However, coinfected liver transplantation
patients present special drug treatment issues because of
drug–drug interactions and the decreased glomerular ﬁltra-
tion rate associated with transplantation.
OTHER THERAPEUTIC CONSIDERATIONS IN
COINFECTED PATIENTS
The majority of adverse events seen in coinfected patients
receiving ART and IFN/RBV combination therapy are those
typically seen in monoinfected patients receiving either
therapy. Therefore, this part of the discussion is devoted to
only those events of particular concern in the coinfected
population. To achieve the SVR rates reported in clinical
trials, patients with hepatitis C must receive IFN and RBV in
recommended doses. However, the adverse effects of medi-
cations are known to result in dose modiﬁcations that can
compromise virologic outcomes.
Anaemia in the coinfected population
Anaemia is common in HIV-infected patients because of
anaemia of chronic disease, blood loss and drug effects.
RBV-related anaemia
Patients with HIV/HCV coinfection present with anaemia
and are more susceptible to its development [79]. Thus, it is
essential to consider the effects of a treatment on Hb
concentration. The most important side effect of RBV is a
dose-dependent haemolytic anaemia [80]. Hb concentra-
tions return to normal within 4–8 weeks after RBV is stop-
ped. RBV-related anaemia is secondary to accumulation of
phosphorylated derivatives of the drug within the erythro-
cyte, competition with high-energy phosphate stores, oxi-
dative stress and extravascular haemolysis. Despite the use
of combination therapy that includes low-dose RBV
(800 mg/day), 12% and 17% of coinfected patients discon-
tinue treatment because of adverse events, primarily haem-
atologic events [57,59]. In one study, anaemia necessitated
dose reductions in 16% of 288 coinfected patients treated
with combination therapy for chronic hepatitis C and in 26%
of those whose antiretroviral regimen included zidovudine
[59]. In 3.8% of patients, Hb dropped to below 8 g/dL,
despite the use of low doses of RBV.
Despite the risk of anaemia, coinfected patients are treated
with HCV combination therapy because of its demonstrated
ability to improve SVR rates. One approach to managing
anaemia is to reduce the dose of RBV or discontinue the
drug. However, virologic outcomes are compromised when
the RBV dose is decreased to 600 mg/day for Hb concen-
trations below 10 g/dL and when RBV is discontinued for Hb
concentrations below 8.5 g/dL. As a result, alternative
strategies and drugs are being evaluated.
Effect of zidovudine on RBV-associated anaemia
Anaemia because of combination therapy with PEG-IFN plus
RBV may be more problematic in HIV-infected patients,
particularly in those receiving concomitant medication such
as zidovudine. In a randomized trial in 107 patients, Brau et
al. [81] reported greater Hb declines during the ﬁrst
16 weeks ()3.64 g/dL) in patients receiving combination
therapy with RBV 800 mg/day plus zidovudine than in pa-
tients who did not receive zidovudine ()2.08 g/dL). In
addition, patients treated with RBV in combination therapy
who also were receiving zidovudine had more anaemia-
related RBV dose reductions than those not receiving zid-
ovudine (60% vs 16%) [82].
Recombinant human erythropoietin
Recombinant human erythropoietin is used successfully to
treat patients with RBV-associated anaemia and does not
adversely affect HCV clearance. In addition to maintaining
the RBV dose, rHuEPO may increase adherence and improve
health-related quality of life [83]. Sulkowski et al. [84] con-
ducted a 16-week, open-label, randomized, parallel-group,
multicenter study in 66 anaemic (Hb £ 12 g/dL) coinfected
patients receiving IFN/RBV for at least 16 weeks. Patients
were randomized 1:1 to receive epoetin alfa 40 000 U s.c.
once weekly or standard of care (no rHuEPO). The rHuEPO
dose was increased by 20 000 U if Hb had not returned to
pretreatment baseline concentrations after 4 weeks. Mean
baseline Hb was 11.1 ± 0.3 g/dL in the rHuEPO group and
did not differ signiﬁcantly from that in the standard of care
group (P ¼ 0.33). Treatment corrected the anaemia in all
patients, including those receiving zidovudine. The mean
increases in Hb concentrations from baseline to week 16 in
the rHuEPO and control groups were 2.6 ± 0.3 and
0.2 ± 0.3 g/dL, respectively (P < 0.001). Treatment with
the recombinant haematopoietic growth factor allowed sig-
niﬁcantly more patients to receive RBV doses above
10.6 mg/kg/day (67% vs 45%; P ¼ 0.09). Health-related
quality-of-life scores were greater and fatigue decreased
signiﬁcantly in the rHuEPO group compared with the
standard of care group. The drug was well tolerated, and
most adverse events were mild to moderate in severity. These
ﬁndings are supported by studies reporting the beneﬁts of
rHuEPO in HCV-monoinfected patients receiving combina-
tion therapy [85].
Recombinant human erythropoietin is uncommonly
associated with some adverse effects: thrombosis, hyperten-
sion and pure red blood cell aplasia [86–88]. However, no
serious rHuEPO-related events occurred in the study by
Sulkowski et al. [84]. Instead, all adverse events occurred in
the control group and consisted of one case each of chest
pain, myocardial infarction and psychosis. Notably, no
thrombotic events or pure red blood cell aplasia were
reported. Use of the recombinant haematopoietic growth
factor requires regular Hb monitoring. Unfortunately, clin-
ical studies have yet to establish the effect of rHuEPO on
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beneﬁcial effects of prophylactic rHuEPO on quality of life in
patients with hepatitis C.
Alternatives to RBV
New alternatives to RBV may reduce the risk of anaemia and
the need for rHuEPO in the coinfected population without
compromising virologic outcomes. Taribavirin, a liver-tar-
geting prodrug of RBV, is now in phase 3 clinical trials [89].
A synthetic guanosine analogue, taribavirin, is converted to
RBV by hepatic adenosine deaminase and thus preferentially
targets the liver and shows signiﬁcantly less accumulation
within erythrocytes [89]. Because lower levels of red blood
cell RBV phosphates compete with high-energy phosphate
stores, taribavirin produces less compromise of cellular en-
ergetics than RBV. The pharmacology of the drug suggests
its ability to prevent RBV-associated anaemia in coinfected
patients.
Early studies demonstrated the antiviral potential of tar-
ibavirin. A phase 2 randomized, active-controlled, multi-
center study compared taribavirin and RBV in combination
with PEG-IFN alfa-2a in 180 treatment-naı ¨ve patients with
chronic hepatitis C. At the end of treatment, there were no
signiﬁcant differences between groups in the proportion of
patients with undetectable HCV RNA levels (range: 55–
63%), regardless of HCV genotype [90]. Importantly, signi-
ﬁcantly fewer patients treated with taribavirin developed
anaemia compared with those treated with RBV [4% vs 27%;
P < 0.001 (Fig. 2)] [91]. In fact, anaemia (Hb < 10 g/dL)
did not occur in the viramidine 400 mg b.i.d. group and
occurred in only one patient in the 600 mg b.i.d. group, the
dose selected for phase 3 trials [90]. In contrast, 11% and
27% of the taribavirin 800 mg b.i.d. and RBV 1000/
1200 mg/day groups, respectively, became anaemic.
Currently, taribavirin 600 mg b.i.d. is being compared
with RBV 1000/1200 mg/day in 2 phase 3 trials: VISER1
and VISER2 (VIramidine’s Taribavirin Safety and Efﬁcacy vs
Ribavirin). These studies have completed enrollment are
expected to determine the comparative efﬁcacy of taribavirin
vs RBV and to evaluate the drug’s red blood cell-sparing
properties. If the drug is at least as effective as RBV in
combination therapy and is found to preserve Hb concen-
trations, it may eliminate the issue of RBV-related anaemia
in coinfected patients and prevent the need for dose modiﬁ-
cations or rHuEPO therapy.
Mitochondrial toxicity
Nucleoside analogue reverse transcriptase inhibitors used to
treat HIV in coinfected patients can cause mitochondrial
toxicity, which is identiﬁed by elevated levels of lactate or
pancreatic enzymes. This risk is increased in coinfected pa-
tients also receiving drugs with similar mechanisms of ac-
tion. In the APRICOT and RIBAVIC studies, mitochondrial
toxicity was identiﬁed in 3% and 5% of patients, respectively.
In a prospective analysis of 113 coinfected patients, Laguno
et al. [92] identiﬁed evidence of this disorder in 12% of pa-
tients treated with combination therapy for HCV plus HA-
ART, although most patients were asymptomatic.
Administering didanosine to patients treated with combi-
nation therapy increases the risk of mitochondrial toxicity
[93]. Ribavirin monophosphate inhibits IMPDH, the primary
phosphate donor to didanosine [94]. This inhibition increa-
ses the intracellular concentrations of didanosine triphos-
phate and the occurrence of resultant toxicities such as lactic
acidosis. Therefore, all coinfected patients receiving combi-
nation therapy and ART should be monitored for lipid, lactic
acid and amylase levels. If lactate levels are above 5 mmol/L,
treatment should be stopped immediately and supportive
treatment supplied as needed [95]. Patients with lactate
elevations of 2.1–5 mmol/L can continue with a non-nu-
cleoside reverse transcriptase inhibitor or a regimen without
the causative agent.
Drug–drug interactions
Anti-HCV drugs can produce adverse outcomes in coinfected
patients receiving ART. For example, RBV and pyrimidine
antiretroviral agents such as zidovudine exert antagonistic
effects on HIV replication in vitro [96]. This effect appears to
be secondary to RBV-induced inhibition of the phosphory-
lation of azidothymidine. However, the agent also enhances
the inhibitory effects of purine 2¢,3¢-dideoxynucleosides on
replication of HIV in vitro [97]. Thus, the net inhibitory and
facilitatory activities suggest the effect might not be clinically
important — an observation supported by clinical trial re-
sults [59,62,98]. The package insert for didanosine warns
about potential complications when didanosine is adminis-
tered with RBV. The interaction can produce mitochondrial
0 
10 
20 
30 
40 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
a
n
e
m
i
a
 
(
%
)
  P < 0.001a P < 0.01a P = NS
0 
2 
11 
27 
Viramidine (BID)  Ribavirin 
(n = 47) (n = 43) (n = 45) (n = 45)
400 mg  600 mg  800 mg  1000/1200 mg 
Fig. 2 Anaemia in hepatitis C virus-infected patients treated
with ribavirin or taribavirin.
aAdjusted for multiple com-
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Treatment of HIV/HCV-coinfected patients 381toxicity with lactic acidosis, myopathy, neuropathy and
cardiomyopathy, all of which are presumably secondary to
RBV-dependent increased phosphorylation of didanosine and
mitochondrial DNA polymerase (polymerase-c) damage
[81,99]. In addition, a preliminary report of 62 coinfected
patients raises the issue that treatment with protease
inhibitors coadministered with IFN/RBV combination ther-
apy may decrease the SVR [100]. In the study, patients
receiving HAART with or without a PI had SVR rates of
11.1% and 44.4%, respectively. Clearly, this issue requires
study in a larger trial.
Leucopenia
In the pivotal trials of combination therapy for patients with
chronic hepatitis C, neutropenia resulted in dose reductions
of PEG-IFN alfa-2a and alfa-2b in 24% and 18% of patients,
respectively [64,65]. After IFN therapy, both neutrophil and
lymphocyte counts decline within 2 weeks and stabilize
thereafter [101]. The reduction in granulocytes is more se-
vere when PEG-IFN is given. Soza et al. [102] assessed
combination therapy and neutropenia in 119 patients with
chronic hepatitis C. During treatment, neutrophil counts
decreased by an average of 34%. Documented or suspected
bacterial infections developed in 22 patients (18%), but in no
patient with neutropenia. Some physicians manage neu-
tropenia with IFN dose reduction; however, absolute neu-
trophil counts that trigger this response are variable.
Preliminary studies show ﬁlgrastim (recombinant human
granulocyte-colony-stimulating factor) signiﬁcantly im-
proves neutrophil counts and may be a useful adjuvant is
some settings [101].
CONCLUSIONS
Hepatitis C virus coinfection is common in HIV-positive pa-
tients in the USA and Europe. Because HIV infection can
accelerate progression of HCV-related liver disease, treat-
ment of chronic hepatitis C is generally recommended. Either
virus can alter the outcomes associated with the other. At
this time, up to 40% of coinfected patients can achieve SVR
with combination PEG-IFN plus RBV therapy. However, the
ability to achieve SVR depends on adhering to the recom-
mended doses of both drugs; thus, steps should be taken to
prevent and treat potentially dose-limiting complications,
such as hepatotoxicity, mitochondrial toxicity, anaemia, fa-
tigue, depression and neutropenia. New and investigational
agents have the potential to improve the outcomes and
should be studied in coinfected patients as well as more
traditional HCV-infected subgroups.
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